This information is intended for healthcare professionals based in Belgium and Luxembourg.
If you are not a healthcare professional, click here

Opdivo_Yervoy_Logo Opdivo_Yervoy_Logo Opdivo_Logo Opdivo_Chemotherapy_Logo
Neoadjuvant NSCLC Metastatic NSCLC Mesothelioma
Neoadjuvant NSCLC Metastatic NSCLC Mesothelioma
Renal Cell Carcinoma Urothelial cancer
Renal Cell Carcinoma Urothelial cancer
Advanced MelanomaAdjuvant Melanoma
Adjuvant esophageal (EC or GEJC) 1L adenocarcinoma upper GI 1L or 2L esophageal squamous cell carcinoma (ESCC)
Head & Neck
Hodgkin Lymphoma

WELCOME TO YOUR I-O PORTAL

Your portal with up-to-date educational resources & practical tools to support you in treating your patients with OPDIVO and YERVOY. Select a cancer type below.

What’s new ?

Pr Dooms on 9LA update at 4 years presented at ASCO 2023

OPDIVO in combination with platinum-based chemotherapy is reimbursed as of the 1st of August for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression ≥ 1%

OPDIVO in monotherapy is reimbursed from September 1st for the adjuvant treatment of adults and adolescents of 12 years age and older with fully resected stage IIB or IIC melanoma

Bristol Myers Squibb

Type of Cancers

Thoracic

Melanoma

Head & Neck

Genitourinary
(GU)

Gastro-intestinal (GI)

Hodgkin Lymphoma

Are you pharmacist?
Click here

Are you pathologist?
Click here

CT, chemotherapy